Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket

Published 18/01/2023, 12:50
© Reuters.  Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket
IXIC
-
FUVV
-

Benzinga - Gainers

  • Siyata Mobile Inc. (NASDAQ: SYTA) rose 41.5% to $0.3255 in pre-market trading after gaining 8% on Tuesday.
  • Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) rose 26.4% to $0.60 in pre-market trading after the company announced strategic agreement with the City of Huanggang and signed a new shareholder agreement with FF Global Partners.
  • Celyad Oncology SA (NASDAQ: CYAD) shares rose 26.4% to $2.41 in pre-market trading after jumping 138% on Tuesday. Celyad Oncology recently issued an update on its Celyad 2.0 business strategy, which has been adopted and implemented over the last few months.
  • Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares rose 15.1% to $2.29 in pre-market trading after climbing over 60% on Tuesday. Avenue Therapeutics, during November, posted a Q3 loss of $0.45 per share.
  • PaxMedica, Inc. (NASDAQ: PXMD) shares rose 14% to $3.34 in pre-market trading after gaining around 17% on Tuesday.
  • AVITA Medical, Inc. (NASDAQ: RCEL) rose 12.4% to $9.05 in pre-market trading after gaining around 7% on Tuesday. AVITA Medical, last month, submitted FDA PMA application to expand indication to vitiligo.
  • Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) rose 10.6% to $1.25 in pre-market trading. Citius Pharmaceuticals, last month, reported FY22 earnings results.
  • Aterian, Inc. (NASDAQ: ATER) rose 9.8% to $1.46 in pre-market trading. Aterian shares gained 37% on Tuesday after the company issued Q4 revenue guidance above analyst estimates.
  • Healthcare Triangle, Inc. (NASDAQ: HCTI) rose 8.7% to $0.25 in pre-market trading. Healthcare Triangle, during November, posted a Q3 loss of $0.06 per share.
  • Moderna, Inc. (NASDAQ: MRNA) rose 6.5% to $203.00 in pre-market trading after the company's syncytial virus vaccine candidate met its primary endpoint in a Phase 3 trial.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Losers
  • Arcimoto, Inc. (NASDAQ: FUV) fell 44.4% to $3.40 in pre-market trading after the company reported a proposed public offering.
  • IronNet, Inc. (NYSE: IRNT) shares fell 11.8% to $0.3601 in pre-market trading. IronNet, last month, announced receipt of noncompliance letter from NYSE.
  • The Very Good Food Company Inc. (NASDAQ: VGFC) fell 10.5% to $0.06 in pre-market trading. The Very Good Food Company announced the receivership order, suspension of trading and board member resignation.
  • Edesa Biotech, Inc. (NASDAQ: EDSA) fell 8.9% to $1.33 in pre-market trading. Edesa Biotech shares dropped around 42% on Tuesday after the company reported topline Phase 2b results for its dermatology drug.
  • Hour Loop, Inc. (NASDAQ: HOUR) shares fell 8.7% to $2.61 in pre-market trading after gaining over 5% on Tuesday.
  • SOS Limited (NYSE: SOS) fell 7.7% to $7.56 in pre-market after jumping around 20% on Tuesday.
  • BIT Mining Limited (NYSE: BTCM) shares dropped 6.8% to $4.06 in pre-market trading. BIT Mining shares jumped 42% on Tuesday after the company announced the launch of a new energy efficient LiteCoin/DogeCoin Miner, LD3.
  • Calyxt, Inc. (NASDAQ: CLXT) fell 6.3% to $0.3310 in pre-market trading. Calyxt shares jumped over 90% on Tuesday after the company and Cibus announced a definitive merger agreement.
  • Aptinyx Inc. (NASDAQ: APTX) fell 6.3% to $0.46 in pre-market trading. Aptinyx , during November, posted a Q3 loss of $0.23 per share.
  • MultiMetaVerse Holdings Limited (NASDAQ: MMV) fell 5.5% to $2.71 in pre-market trading. MultiMetaVerse recently announced a letter of intent to acquire a majority equity stake in Taomee.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.